Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet
Diabetes Mellitus, Type 1
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 1
Eligibility Criteria
Inclusion Criteria: HbA1c > 8.5% for more than one year prior to enrolment. Diabetes-duration > 5 years. Age at onset of diabetes < 35 years Fasting C-peptide < 300 pmol/l Age > 18 years at enrolment. Exclusion Criteria: Clinical or biochemical signs of kidney-, liver- or heart-failure. Other coexisting serious morbidity, which will affect the study-participation or outcome of the study i.e. cancer. Known abuse of any medication or alcohol Hypoglycaemia unawareness. Pregnancy or planned pregnancy in the study-period.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Placebo Comparator
Active Comparator
Placebo Comparator
1
2
3
Single-blind placebo run-in period. Duration one month.
Metformin 2000 mg, double-masked randomized during 12 months.
Placebo, double-masked randomized during 12 months.